Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 8c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.42 --0%
Revenue Growth %: +5.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +5.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.26, $0.08 better than the analyst estimate of $0.18. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $53.62 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2022 revenue of $205-210 million, versus the consensus of $205 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
